Mapping the EQ-5D index from the cystic fibrosis questionnaire-revised using multiple modelling approaches

Health and Quality of Life Outcomes

Volumn 13, Issue 1, 2015, Pages

  Acaster, Sarah ^a   Pinder, Binny ^a   Mukuria, Clara ^b   Copans, Amanda ^c  

^a ICON PLC   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c GILEAD SCIENCES   (United States)

Author keywords

CFQ R; EQ 5D; Health utilities; Mapping; Quality of life

Indexed keywords

ADULT; AGE; ALGORITHM; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; CROSS-SECTIONAL STUDY; CYSTIC FIBROSIS; CYSTIC FIBROSIS QUESTIONNAIRE-REVISED; DISEASE ASSESSMENT; ECONOMIC EVALUATION; EQ-5D QUESTIONNAIRE; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; QUALITY OF LIFE ASSESSMENT; REGRESSION ANALYSIS; STATISTICAL MODEL; UNITED KINGDOM; BAYES THEOREM; GREAT BRITAIN; HEALTH STATUS INDICATOR; PSYCHOLOGY; QUALITY OF LIFE; QUESTIONNAIRE; STANDARDS; THEORETICAL MODEL;

ADULT; ALGORITHMS; BAYES THEOREM; CROSS-SECTIONAL STUDIES; CYSTIC FIBROSIS; FEMALE; GREAT BRITAIN; HEALTH STATUS INDICATORS; HUMANS; MALE; MODELS, THEORETICAL; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES;

EID: 84928750956     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/s12955-015-0224-6     Document Type: Article

References (29)

1. Cohen-Cymberknoh M, Shoseyov D, Kerem E. Managing cystic fibrosis: Strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med. 2011;183:1463-71.
2. Royce FH, Carl JC. Health-related quality of life in cystic fibrosis. Curr Opin Pediatr. 2011;23:535-40.
3. Quittner AL. Measurement of quality of life in cystic fibrosis. Curr Opin Pulm Med. 1998;4:326-31.
4. Wahl AK, Rustoen T, Hanestad BR, Gjengedal E, Moum T. Living with cystic fibrosis: impact on global quality of life. Heart Lung. 2005;34:324-31.
5. Britto MT, Kotagal UR, Hornung RW, Atherton HD, Tsevat L. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest. 2002;121:64-72.
6. Quittner AL, Buu A, Messer MS, Modi AC, Watrous M. Development and validation of the cystic fibrosis questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest. 2005;128:2347-54.
7. Quittner AL, Buu A, Watrous M, Davis MA. The cystic fibrosis questionnaire (CFQ): user's manual. Washington, DC: Cystic Fibrosis Foundation; 2000.
8. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med. 2006;354:241-50.
9. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, et al. National hypertonic saline in cystic fibrosis (NHSCF) study group: a controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006;354:229-40.
10. National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2013. NICE. 2013. http://www.nice.org.uk/article/pmg9/resources/non-guidance-guide-to-the-methods-of-technology-appraisal-2013-pdf .
11. Sauerland S, Weiner S, Dolezalova K, Angrisani L, Noguera CM, Garcia-Caballero M, et al. Mapping utility scores form a disease-specific quality of life measure in bariatric surgery patients. Value Health. 2009;12:364-70.
12. Franks P, Lubetkin EI, Gold MR, Tancredi DJ, Jia H. Mapping the SF-12 to the EuroQol EQ-5D index in a national US sample. Med Decis Making. 2004;24:247-54.
13. Ara R, Brazier J. Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference -based score from published studies (where patient level data are not available). Value Health. 2008;11:1131-43.
14. Longworth L, Rowen D. Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value Health. 2013;16:202-10.
15. Brazier JR, Yang Y, Tsuchiya A, Rowen DL. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ. 2010;11:215-25.
16. Rabin R, de Charro F. EQ-D5: a measure of health status from the EuroQol group. Ann Med. 2001;33:337-43.
17. Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:53-72.
18. Group EQ. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199-208.
19. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095-8.
20. Chuang L-H, Whitehead SJ. Mapping for economic evaluation. Br Med Bull. 2012;101:1-15.
21. Dakin H, Petrou S, Haggard M, Benge S, Williamson I. Mapping analyses to estimate health utilities based on responses to the OM8-30 Otitis Media Questionnaire. Qual Life Res. 2010;19:65-80.
22. Chuang L-H, Kind P. Converting the SF-12 into the EQ-5D: an empirical comparison of methodologies. Pharmacoeconomics. 2009;27:491-505.
23. Huang IC, Frangakis C, Atkinson MJ, Willke RJ, Leite WL, Vogel WB, et al. Addressing ceiling effects in health status measures: a comparison of techniques applied to measures for people with HIV disease. Health Serv Res. 2008;43:327-39.
24. Quittner AL, Sawicki GS, McMullen A, Rasouliyan L, Pasta DJ, Yegin A, et al. Psychometric evaluation of the cystic fibrosis questionnaire-revised in a national, US sample. Qual Life Res. 2012;21:1279-90.
25. Bradley JM, Blume SW, Balp M-M, Honeybourne D, Elborn JS. Quality of life and healthcare utilisation in cystic fibrosis: a multicentre study. Eur Respir J. 2013;41:571-7.
26. Versteegh M, Rowan DL, Brazier JE, Stolk EA. Mapping onto EQ-5D for patients for patients in poor health. Health Qual Life Outcomes. 2010;8:141.
27. Rowan DL, Brazier JE, Roberts J. Mapping SF-36 onto the EQ-5D index: how reliable is the relationship? Health Qual Life Outcomes. 2009;7:27.
28. Sanders DB, Bittner RCL, Rosenfeld M, Redding GJ, Goss CH. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol. 2011;46:393-400.
29. Jarad NA, Higgs S, Jeffcote T, Giles K. Factors associated with reduced FEV1 in adult patients with cystic fibrosis in a relatively affluent area. Chron Respir Dis. 2005;2:133-7.